Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoDTM Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Cancer Oncology

Internal Medicine

Medicine

Cancer Oncology

Internal Medicine

Genetics

First Line

Show all topics

DOI

10.1016/s2152-2650(24)00397-5